IP Library Patent Application 17214416
Patent Application
App. No. 17/214,416

AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/214,416
Abstract

Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

Claims (15)

1 - 22 . (canceled)

23 . A method of treating a bacterial lung infection caused by one or more of the following bacteria: Pseudomonas aeruginosa, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare , and Mycobacterium leprae , comprising administering a pharmaceutical aerosol for nasal, sinunasal or pulmonary administration comprising a dispersed liquid phase and a continuous gas phase, wherein the dispersed liquid phase:

(a) consists essentially of aqueous droplets comprising levofloxacin, and at least one excipient comprising a multivalent metal ion;

(b) has a mass median diameter from about 1 to about 5 sm; and

(c) has a droplet size distribution exhibiting a geometrical standard deviation less than or equal to about 3.0 sm.

24 . The method of claim 23 , wherein at least about 20 mg of levofloxacin is administered to the lung.

25 . The method of claim 24 , wherein at least about 100 mg of levofloxacin is administered to the lung.

26 . The method of claim 25 , wherein at least about 125 mg of levofloxacin is administered to the lung.

27 . The method of claim 26 , wherein at least about 150 mg of levofloxacin is administered to the lung.

28 . The method of claim 23 , wherein the aerosol is administered to the lung in less than about 10 minutes.

29 . The method of claim 28 , wherein the aerosol is administered to the lung in less than about 5 minutes.

30 . The method of claim 29 , wherein the aerosol is administered to the lung in less than about 3 minutes.

31 . The method of claim 30 , wherein the aerosol is administered to the lung in less than about 2 minutes.

32 . The method of claim 23 , comprising administering the aerosol once daily.

33 . The method of claim 23 , comprising administering the aerosol twice daily.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2021
From: MPEX PHARMACEUTICALS, INC.
To: TRIPEX PHARMACEUTICALS, LLC
Reel/Frame 056383/0920 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2021
From: TRIPEX PHARMACEUTICALS, LLC
To: RAPTOR PHARMACEUTICALS INC.
Reel/Frame 056422/0235 →
CHANGE OF NAME Recorded May 28, 2021
From: RAPTOR PHARMACEUTICALS INC.
To: HORIZON ORPHAN LLC
Reel/Frame 056424/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2021
From: SURBER, MARK W; BOSTIAN, KEITH A; DUDLEY, MICHAEL N; LOMOVSKAYA, OLGA; GRIFFITH, DAVID C
To: MPEX PHARMACEUTICALS, INC.
Reel/Frame 056377/0274 →